pomalidomide has been researched along with canertinib in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 124 | 9 | 65 |
| Protein | Taxonomy | pomalidomide (IC50) | canertinib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0068 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0757 | |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | 0.0395 | |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.324 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 2.94 | |
| Dipeptidyl peptidase 1 | Homo sapiens (human) | 2.7 | |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.185 | |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | 5.65 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0103 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, B; Liu, H; Qiu, X; Qu, X; Song, X; Sun, N; Yang, X; Zhong, H | 1 |
1 other study(ies) available for pomalidomide and canertinib
| Article | Year |
|---|---|
Effective degradation of EGFR
Topics: Apoptosis; Autophagy; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lysosomes; Molecular Structure; Morpholines; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Structure-Activity Relationship; Thalidomide | 2021 |